drugset
drugset / Trial / NCT02130700

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

NCT02130700 ↗

Phase 2 Completed 17 enrolled Innocrin Pharmaceutical National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men with ER positive Breast Cancer.

Timeline

Start
2014-04
Primary completion
2017-09
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Seviteronel Small molecule — Oral

Indications

prostate cancer